Sophiris Bio (Sophiris Bio) Change In Inventory : $0.00 Mil (TTM As of Sep. 2019)

View and export this data going back to 2013. Start your Free Trial

What is Sophiris Bio Change In Inventory?

Sophiris Bio's change in inventory for the quarter that ended in Sep. 2019 was $0.00 Mil. It means Sophiris Bio's inventory stayed the same from Jun. 2019 to Sep. 2019 .

Sophiris Bio's change in inventory for the fiscal year that ended in Dec. 2018 was $0.00 Mil. It means Sophiris Bio's inventory stayed the same from Dec. 2017 to Dec. 2018 .

Sophiris Bio's Total Inventories for the quarter that ended in Sep. 2019 was $0.00 Mil.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Inventory Turnover measures how fast the company turns over its inventory within a year.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Sophiris Bio Change In Inventory Historical Data

The historical data trend for Sophiris Bio's Change In Inventory can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sophiris Bio Change In Inventory Chart

Sophiris Bio Annual Data

Trend

Dec09

Dec10

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Change In Inventory

Get a 7-Day Free Trial

Sophiris Bio Quarterly Data
	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19
Change In Inventory	Get a 7-Day Free Trial															-	-	-	-	-

Sophiris Bio Change In Inventory Calculation

Change In Inventory is the difference between last period's ending inventory and the current period's ending inventory.

Change In Inventory for the trailing twelve months (TTM) ended in Sep. 2019 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

Sophiris Bio (OTCPK:SPHS) Change In Inventory Explanation

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Sophiris Bio's Days Inventory for the quarter that ended in is calculated as:

Days Inventory	=	Average Total Inventories	/	Cost of Goods Sold	*	Days in Period
	=	0	/	0	*	365 / 4
	=	N/A

2. Inventory Turnover measures how fast the company turns over its inventory within a year.

Sophiris Bio's Inventory Turnover for the quarter that ended in Sep. 2019 is calculated as

Inventory Turnover	=	Cost of Goods Sold	/	Average Total Inventories
	=	0	/	0
	=	N/A

3. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Sophiris Bio's Inventory to Revenue for the quarter that ended in Sep. 2019 is calculated as

Inventory-to-Revenue	=	Average Total Inventories	/	Revenue
	=	0	/	0
	=	N/A

Sophiris Bio Change In Inventory Related Terms

Thank you for viewing the detailed overview of Sophiris Bio's Change In Inventory provided by GuruFocus.com. Please click on the following links to see related term pages.

Sophiris Bio (Sophiris Bio) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sophiris Bio Inc (OTCPK:SPHS) » Definitions » Change In Inventory

Comparable Companies

Traded in Other Exchanges

N/A

Address

1258 Prospect Street, La Jolla, CA, USA, 92037

Website

http://www.sophirisbio.com

Sophiris Bio Inc is a clinical-stage biopharmaceutical company. It focuses on the development of products for the treatment of urological diseases. The company's product portfolio includes topsalysin (PRX302), for the treatment of lower urinary tract symptoms of benign prostatic hyperplasia (BPH), as well as for the treatment of localized low to intermediate risk prostate cancer. Topsalysin is a genetically modified recombinant protein which is selectively activated by enzymatically active prostate-specific antigen (PSA), which is only present in the prostate, leading to localized cell death and tissue disruption without damage to neighboring tissue and nerves. Geographically all the operations of the company are functioned in the United States.

Executives

Randall E Woods	director, officer: President & Chief Exec Officer	C/O ARENA PHARMACEUTICALS, INC. 6166 NANCY RIDGE DRIVE SAN DIEGO CA 92121
Lars Ekman	director	C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949
James L Heppell	director
Gerald T Proehl	director
John Geltosky	director	685 ROUTE 202/206, BRIDGEWATER NJ 08807
Joseph L Turner	director	10505 ROSELLE STREET, SAN DIEGO CA 92121
Joseph Lewis	10 percent owner	PO BOX N7776, LYFORD BAHAMAS
Boxer Asset Management Inc.	10 percent owner	CAY HOUSE, EP TAYLOR DRIVE N7776, LYFORD CAY, NEW PROVIDENCE C5 00000
Boxer Capital, Llc	10 percent owner	12860 EL CAMINO REAL, SUITE 300, SAN DIEGO CA 92130
Mva Investors, Llc	10 percent owner	12860 EL CAMINO REAL, SUITE 300, SAN DIEGO CA 92130
William R Rohn	director	PO BOX 676367, RANCHO SANTA FE CA 92067